Back

An in vivo avian model of human melanoma to perform rapid and robust preclinical studies

Jarrosson, L.; Dalle, S.; Costechareyre, C.; Tang, Y.; Grimont, M.; Plaschka, M.; Lacourrege, M.; Teinturier, R.; Le Bouar, M.; Maucort-Boulch, D.; Eberhardt, A.; Castellani, V.; Caramel, J.; Delloye-Bourgeois, C.

2022-10-13 cancer biology
10.1101/2022.10.12.511927 bioRxiv
Show abstract

Metastatic melanoma patients carrying a BRAFV600 mutation can be treated with BRAF inhibitors (BRAFi), in combination with MEK inhibitors (MEKi), but innate and acquired resistance invariably occurs. Resistance can involve transcriptional- and epigenetic-based phenotypic adaptations, as yet unpredictable. Predicting patient response to targeted therapies is crucial to guide clinical decision. We describe here the development of a highly efficient patient-derived xenograft model adapted to patient melanoma biopsies, using the avian embryo as a host (AVI-PDX). In this in vivo paradigm, we depict a fast and reproducible tumor engraftment of patient samples within the embryonic skin, preserving key molecular and phenotypic features. We show that sensitivity and resistance to BRAFi/MEKi targeted therapies can be reliably modeled in these AVI-PDX, as well as synergies with other drugs, such as HDACi. We further provide proof-of-concept that the AVI-PDX models the diversity of responses of melanoma patients to BRAFi/MEKi, within days, hence positioning it as a valuable tool for the design of personalized medicine assays and for the evaluation of novel combination strategies.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.1%
13.1%
Similar papers in this journal
2
Nature Communications
○ 5641 papers in training set
Top 15%
12.1%
Similar papers in this journal
3
Cell Reports Medicine
○ 153 papers in training set
Top 0.2%
6.8%
Similar papers in this journal
4
eLife
● 5828 papers in training set
Top 27%
4.4%
Similar papers in this journal
5
iScience
○ 1154 papers in training set
Top 3%
4.4%
Similar papers in this journal
6
Journal of Experimental & Clinical Cancer Research
○ 25 papers in training set
Top 0.1%
4.1%
7
Disease Models & Mechanisms
139 papers in training set
Top 0.5%
4.1%
8
Cancers
○ 213 papers in training set
Top 2%
3.3%
50% of probability mass above
9
Scientific Reports
○ 3612 papers in training set
Top 40%
2.5%
10
Cancer Research
● 130 papers in training set
Top 1%
2.4%
11
EMBO Reports
○ 263 papers in training set
Top 2%
2.4%
12
Communications Biology
○ 993 papers in training set
Top 8%
2.4%
13
Science Advances
● 1243 papers in training set
Top 19%
1.8%
14
Cell Reports
○ 1498 papers in training set
Top 18%
1.8%
15
Journal of Experimental Medicine
● 119 papers in training set
Top 2%
1.4%
16
Molecular Therapy Oncology
○ 10 papers in training set
Top 0.1%
1.1%
17
Pigment Cell & Melanoma Research
○ 11 papers in training set
Top 0.2%
1.1%
18
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.5%
1.1%
19
Frontiers in Oncology
○ 103 papers in training set
Top 3%
1.1%
20
Cell Reports Methods
○ 165 papers in training set
Top 3%
1.0%
21
Molecular Therapy
○ 81 papers in training set
Top 2%
0.9%
22
Antiviral Research
○ 50 papers in training set
Top 0.6%
0.9%
23
Nature Cancer
○ 39 papers in training set
Top 1%
0.9%
24
Journal of Clinical Investigation
● 179 papers in training set
Top 5%
0.9%
25
International Journal of Cancer
○ 49 papers in training set
Top 1%
0.9%
26
Molecular Cancer
○ 16 papers in training set
Top 0.4%
0.6%
27
Cells
○ 249 papers in training set
Top 8%
0.6%
28
Frontiers in Cell and Developmental Biology
○ 233 papers in training set
Top 6%
0.6%
29
Stem Cell Reports
○ 130 papers in training set
Top 2%
0.6%
30
The EMBO Journal
○ 309 papers in training set
Top 7%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.